VRX.TO - Valeant Pharmaceuticals International, Inc.

Toronto - Toronto Delayed Price. Currency in CAD
Show:
Income Statement
Balance Sheet
Cash Flow

Income Statement

Annual
Currency in USD. All numbers in thousands
Revenue12/31/201712/31/201612/31/201512/31/2014
Total Revenue8,724,0009,674,00010,442,0008,200,000
Cost of Revenue2,548,0002,573,0002,446,0002,203,000
Gross Profit6,176,0007,101,0007,996,0005,997,000
Operating Expenses
Research Development361,000421,000334,000246,000
Selling General and Administrative2,582,0002,810,0002,677,0002,026,000
Non Recurring----
Others-353,00018,00028,00028,000
Total Operating Expenses7,828,0008,495,0007,742,0005,902,000
Operating Income or Loss896,0001,179,0002,700,0002,298,000
Income from Continuing Operations
Total Other Income/Expenses Net-2,637,000-3,614,000-2,855,000-1,244,000
Earnings Before Interest and Taxes896,0001,179,0002,700,0002,298,000
Interest Expense-1,840,000-1,836,000-1,563,000-971,000
Income Before Tax-1,741,000-2,435,000-155,0001,054,000
Income Tax Expense-4,145,000-27,000133,000174,000
Minority Interest-106,000119,000122,300
Net Income From Continuing Ops2,404,000-2,408,000-288,000880,000
Non-recurring Events
Discontinued Operations----
Extraordinary Items----
Effect Of Accounting Changes----
Other Items----
Net Income
Net Income2,404,000-2,409,000-292,000881,000
Preferred Stock And Other Adjustments----
Net Income Applicable To Common Shares2,404,000-2,409,000-292,000881,000